OIPE
AUG 25 2006
PATENT & TRADEMARK OFFICE

IFW

PTO/SB/21 (04-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paper Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/780,325
Filing Date	02/17/2004
Inventors	Steven C. Quay et. al.
Art Unit	1653
Examiner Name	Rosanne Kosson
Total Number of Pages in This Submission: 28	Attorney Docket Number: 02-04CIP3, Project 0189

ENCLOSURES *(Check all that apply)*

- [x] **Fee Transmittal Form**
 - [x] Fee Attached $180
- [] Amendment / Reply
 - [] Request to Correct Priority Claim
 - [] Affidavits/declaration(s)
- [] Extension of Time Request
- [x] **IDS form 1449/ SB08B, 1 pages**
- [x] **Information Disclosure Statement- 2 pages**
- [] Certified Copy of Priority Document(s)
- [] Response to Missing Parts/ Incomplete Application
 - [] Response to Missing Parts under 37 CFR 1.52 or 1.53
- [] Drawing(s)
- [] Licensing-related Papers
- [] Petition
- [] Petition to Convert to a Provisional Application
- [] Declaration and Power of Attorney, Declaration, 2 pages
- [] Terminal Disclaimer
- [] Request for Refund
- [] CD, Number of CD(s) _____
- [] After Allowance communication to Technology Center (TC)
- [] Appeal Communication to Board of Appeals and Interferences
- [] Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- [] Proprietary Information
- [] Status Letter
- [x] Other Enclosure(s) (please identify below):

Return Receipt Postcard

Remarks

Reporting prior art from PCT search report dated 4-25-2006

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Nastech Pharmaceutical Company Inc., Peter J. Knudsen Reg. No. 40,682
Signature	
Date	August 22, 2006

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Kerry King		
Signature	Kerry King	Date	August 22, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OIPE
AUG 2 5 2006
PATENT & TRADEMARK OFFICE

PTO/SB/17 (01-06)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL
For FY 2006

	Complete if Known
Application Number	10/780,325
Filing Date	02/17/2004
First Named Inventor	Steven C. Quay
Examiner Name	Rosanne Kosson
Art Unit	1653
Attorney Docket No.	02-04CIP3, Project 0189

[X] Applicant Claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT ($) 180.00

METHOD OF PAYMENT (check all that apply)

[] Check [] Credit Card [] Money Order [] None [] Other (please identify):_____

[X] Deposit Account Deposit Account Number: 502769 Deposit Account Name: Nastech Pharmaceutical Company Inc.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

[X] Charge fee(s) indicated below [] Charges fee(s) indicated below, **except for the filing fee**

[X] Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 [X] Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.)

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		Small Entity		Small Entity		Small Entity	
Application Type	Fee ($)	Fee ($)	Fee ($)	Fee ($)	Fee ($)	Fee ($)	Fees Paid ($)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES

Fee Description	Fee ($)	Small Entity Fee ($)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims		Extra Claims	Fee ($)		Fee Paid ($)
0	- 20 or HP =	0	x $25.00	=	$ 0.00

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims		Extra Claims	Fee ($)		Fee Paid ($)
0	- 3 or HP =	0	x $100.00	=	$ 0.00

HP = highest number of independent claims paid for, if greater than 3.

Multiple Dependent Claims Fee ($)	Fee Paid ($)
$180.00	

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is $250 ($125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41 (a)(1)(G) and 37 CFR 1.16(s).

Total Sheets		Extra Sheets		Number of each additional 50 or fraction thereof		Fee ($)		Fee Paid ($)
0	- 100 =	0	/ 50 =	0	(round up to a whole number) x	$125.00	=	$ 0.00

4. OTHER FEE(S)

	Fees Paid($)
Non-English Specification, $130 fee (no small entity discount)	
Other (e.g., late filing surcharge): IDS	$180.00

SUBMITTED BY

Signature	Registration No. (Attorney/Agent) 40,682	Telephone 425-908-3643
Name (Print/Type) Peter J. Knudsen		Date 8/22/2006

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

OIPE
AUG 2 5 2006
PATENT & TRADEMARK OFFICE
IAP58

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Steven C. Quay, *et. al.*	Assignee: Nastech Pharmaceutical Company Inc. by Reel 014680/Frame 0942
U.S. Application Serial No.: 10/780,325	
Filing Date: 02/17/2004	Examiner: Rosanne Kosson Group Art Unit: 1653
Title: COMPOSITIONS AND METHODS FOR ENHANCED MUCOSAL DELIVERY OF Y2 RECEPTOR-BINDING PEPTIDES AND METHODS FOR TREATING AND PREVENTING OBESITY	
Attorney Docket No.: 02-04CIP3	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

___ under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

X under 37 CFR 1.97(c) together with either a:
___ Statement under 37 CFR 1.97(e), or
X a $180.00 fee under 37 CFR 1.17(p), or
(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

___ under 37 CFR 1.97(d) together with a:
___ Statement under 37 CFR 1.97(e), and
___ a $180.00 fee set forth in 37 CFR 1.17(p).
(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

08/28/2006 DEMMANU1 00000016 502769 10780325
01 FC:1806 180.00 DA

X Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies of publications and the International Search Report and the Written Opinion of the related PCT Application, which applicant believes may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that this is the closest art of which Applicant is aware. Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

I hereby certify that this Correspondence is being deposited with the United States Postal service with sufficient postage for first class mail in an envelope address to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or the correspondence is being facsimile transmitted to the USPTO, on the date indicated below.

Date of Deposit: 8/22/2006

Typed Name: Kerry King

Signature: Kerry King

Peter J. Knudsen, Reg. No.: 40,682
Attorney for Applicants
Nastech Pharmaceutical Company Inc.
3450 Monte Villa Parkway
Bothell, WA 98021
(425) 908-3643 - Phone
(425) 908-3653 - Fax
pknudsen@nastech.com

OIPE
AUG 25 2006
IAP58
PATENT & TRADEMARK OFFICE

PTO/SB/08a (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	**10/780,325**
Filing Date	02/17/2004
First Named Inventor	Quay, Steven C.
Art Unit	1653
Examiner Name	Rosanne Kosson
Attorney Docket Number	02-04CIP3, Project 0189

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
		ANONYMOUS: "Nastech Begins a Clinical Trial with Intranasal PYY in Overweight Adults," DAILYDRUGNEWS.COM, DAILY ESSENTIALS, 23 January 2004 (2004-01-23), XP001207998	
		CERVIN, ANDERS, ET AL: "Functional Effects of Neuropeptide Y Receptors on Blood Flow and Nitric Oxide Levels in the Human Nose," AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, pp. 1724-1728 v. 160, no. 5, Part I, November 1999 (1999-11), XP002376387; ISSN: 1073-449X	
		SUMAN, JULIE D. ET AL: "Validity of *In Vitro* Tests on Aqueous Spray Pumps as Surrogates for Nasal Deposition," PHARMACEUTICAL RESEARCH (NEW YORK), pp. 1-6, v. 19, no. 1, January 2002 (2002-01), XP002376388, ISSN: 0724-8741	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.